BPC-157 + TB-500 Blend
Multi-component research blend
A research-supplier blend pairing BPC-157 with TB-500, two peptides commonly studied together in tissue-repair research.
Also referenced as: BPC-157/TB-500 blend
Overview
This is a research blend combining BPC-157 and TB-500 (a Thymosin Beta-4-related fragment). It is not a naturally occurring substance and exists only as a combination formulated for research contexts.
At a glance
What BPC-157 + TB-500 Blend does
The BPC-157 / TB-500 blend combines two of the most-studied research repair peptides, pairing complementary mechanisms so the mix targets tissue healing from two directions at once. BPC-157 contributes angiogenic and cytoprotective signaling, promoting new blood-vessel growth (via VEGFR2 and the nitric-oxide/eNOS system) and protecting and rebuilding connective tissue and gut lining. TB-500 (thymosin beta-4) contributes actin-cytoskeleton regulation that accelerates cell migration, along with its own angiogenic and anti-inflammatory actions. The rationale is that BPC-157 improves the local vascular and cytoprotective environment while TB-500 mobilizes cells to migrate into and remodel the injury.
In practice the blend is used in musculoskeletal-repair research contexts (tendon, ligament, muscle, and soft-tissue injury), on the theory that combining a systemic actin-regulating migration factor with a locally cytoprotective angiogenic factor yields broader and possibly faster repair than either alone. Both peptides independently increase angiogenesis and collagen organization and reduce inflammation in animal models, so the combination is expected to reinforce those overlapping endpoints.
The critical caveat is that this is a formulation of convenience, not a separately validated drug. The supporting evidence is the preclinical literature on each component individually; there are no rigorous human clinical trials of the combination, and no controlled studies confirming that the blend outperforms either peptide alone. Effects attributed to it are inferred from the two components' documented actions.
Effects reported in research
- Combines BPC-157's angiogenic/cytoprotective signaling with TB-500's actin-regulated cell-migration effects for complementary tissue repair (rationale from component data).
- Both components independently promote angiogenesis, so the blend reinforces new blood-vessel formation at injury sites (animal/in-vitro).
- BPC-157 contributes VEGFR2 and nitric-oxide/eNOS-driven vascular and cytoprotective effects (animal/in-vitro).
- TB-500 contributes G-actin sequestration that accelerates the cell migration underlying wound closure and remodeling (established biochemistry).
- Both reduce pro-inflammatory signaling, so the blend is expected to dampen inflammation in injured tissue (animal/in-vitro).
- Targeted in research at tendon, ligament, muscle, and soft-tissue repair based on each peptide's musculoskeletal data (animal only).
- No human clinical trials validate the combination; all support is preclinical and inferred from the individual peptides.
- Formulation and ratios vary by supplier; the blend is not a separately standardized or approved product.
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
As a blend, it combines the documented properties of its components: BPC-157, studied in animal models for angiogenesis and growth-factor-related tissue-repair signaling, and TB-500, associated with actin regulation and cell migration in preclinical work. Any combined effect is not independently characterized in controlled human trials.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which BPC-157 + TB-500 Blend appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- Combines the documented properties of BPC-157 and TB-500
- Not a single defined molecule but a two-component blend
- Evidence for each component is largely preclinical; the blend itself is not clinically validated
- Neither component is an approved drug
- Frequently marketed together for connective-tissue and recovery research
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. BPC-157 + TB-500 Blend is a research compound.
Blend protocols reported in research summaries generally follow TB-500's weekly milligram schedule while co-delivering a proportional amount of BPC-157, since the two are fixed in the vial. These are reference figures for research context only, not dosing guidance for humans.
- Common 1:1 vials: 5 mg + 5 mg (10 mg total) or 10 mg + 10 mg (20 mg total)
- Reconstitution example (10 mg blend): ~3 mL bacteriostatic water gives ~1.67 mg/mL of each peptide
- Protocol anchor: TB-500 component ~2-10 mg/week split into 2-3 doses, co-delivering BPC-157 at the same 1:1 ratio
Fixed 1:1 ratio means BPC-157 and TB-500 amounts cannot be adjusted independently once blended. Both components are research-only; figures are reference figures.
How it compares
This blend pairs a growth-factor/angiogenesis-focused peptide (BPC-157) with an actin-regulating fragment (TB-500), differing from single-peptide or copper-tripeptide products.
Blend components
This entry documents a research-supplier blend combining the following. Each component is documented as its own PeptiDex entry where available:
Commonly studied alongside
Compounds frequently researched together with BPC-157 + TB-500 Blend in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Compare and calculate
Side-by-side pages for the pairings the literature already documents for BPC-157 + TB-500 Blend, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
BPC-157 + TB-500 Blend sits in the Healing & Recovery area of the PeptiDex library.
- Entry type: Research-supplier blend
- Healing & Recovery category hub →
- Browse the full library →
- Glossary of terms →
Where researchers source BPC-157 + TB-500 Blend
For researchers studying BPC-157 + TB-500 Blend, third-party suppliers such as Practically Natty Peptides offer research-grade material, third-party tests every batch and provides Certificates of Analysis on request, and ship from the US.
View research-supplier listing →
Outbound link to a third-party research supplier. Inclusion does not constitute endorsement; all editorial content is developed independently.
Frequently asked questions
What is the BPC-157 + TB-500 blend?
It is a combined research formulation pairing BPC-157 with TB-500 (thymosin beta-4 related peptide), the two most widely co-studied tissue-repair peptides. Vials are commonly supplied at a 1:1 ratio, for example 5 mg of each (10 mg total) or 10 mg of each (20 mg total). Every dose drawn provides both peptides in the same proportion.
Why are BPC-157 and TB-500 combined?
They are combined because their proposed repair mechanisms are viewed as complementary: BPC-157 is associated with angiogenesis and nitric-oxide signaling, while TB-500 relates to actin regulation and cell migration. In tissue-repair research this pairing is the classic 'systemic + local' repair stack. Any synergy claims remain preclinical and unproven in humans.
How is the blend reconstituted and dosed in research?
For a 10 mg blend (5 mg + 5 mg), adding about 3 mL of bacteriostatic water yields roughly 3.33 mg/mL total (about 1.67 mg/mL of each peptide). Because the two peptides differ in typical dosing scale, protocols usually anchor to the TB-500 milligram schedule while accepting the co-delivered BPC-157 amount. These are reference figures, not dosing guidance.
How should the blend be stored?
Reconstitute by adding bacteriostatic water slowly down the vial wall and swirling gently rather than shaking. Store the reconstituted solution refrigerated at 2-8 C, protected from light, and label with the date. Lyophilized blend is more stable and can be frozen for longer-term storage.
Is the BPC-157 + TB-500 blend an approved drug?
No. Neither component is approved and the blend is sold strictly for research use; both peptides are also prohibited in sport under WADA. All repair-related evidence is from preclinical animal models.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.
References
No indexed primary literature located for this compound as of 2026-07-28. PubMed was searched for work specific to BPC-157 + TB-500 Blend and none was found.
PeptiDex states this plainly rather than citing a study of a different compound to fill the space — the same null-not-guessed rule the specification table follows. See the editorial policy.